Investigation of Fixed Triple Inhaled Combination in Asthmatic Patients, in a Real-life Setting

Recruiting now

Conditions studied: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Asthma Bronchiale

In brief

The mainstay of asthma treatment are ICSs, mostly combined with LABA. In the past decade LAMA had been accepted as an add-on treatment for patients on GINA treatment Steps 4 and 5. Recently, RCTs proved the efficacy and safety of fixed triple combinations of moderate and high dose of ICS and LABA, LAMA in a very selected asthmatic population, resulting in the market authorisation of these products. However, there is a lack of evidence on the real-world effectiveness of these therapies, especially with regards to improvement in symptom scores and quality of life. Also, there is scarcity of data regarding the phenotypes of asthmatics who benefit the most from the use of fixed triple combinations.

Key facts

Study ID
NCT06678191
Run by
Chiesi Hungary Ltd.
People needed
800
Starts
2024-10-24
Expected to finish
2027-08-31
Last updated by the study team
2024-11-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.